The Fleming Fund – Evaluation Supplier
key details
| Status | planning |
|---|---|
| Category (CPV) | 72221000 +6 more |
| SME suitable | No |
| OCID | ocds-b5fd17-4b3abf5a-adc9-11e6-9901-0019b9f3037b |
description
The UK Government has announced the Fleming Fund to support low and middle income countries in tackling antimicrobial resistance (AMR) through addressing the gaps with good quality assured data and surveillance. Drug-resistant infections could kill an extra 10 million people across the world every year by 2050 if they are not tackled. They could also cost the world around $100 trillion in lost output: more than the size of the current world economy (Review on Antimicrobial Resistance, 2014).
Both the Prime Minister and Chief Medical Officer have announced that tackling AMR at home and abroad is a key priority and that the UK will help to lead a global response in this field. To facilitate this, the Department of Health (DH) is working closely with the Department for International Development (DFID) to establish programmes aimed at supporting low and middle income countries, where there remains very little data on the extent of the problem or what priority actions should be taken.
Description of the procurement:
DH will release a tender for an evaluation supplier to deliver an independent long-term performance evaluation of whether the Fleming Fund have achieved its outcomes and impacts, providing formative recommendations to improve implementation, and, a summary of its effects based upon initial evidence. The contract will be for a five year evaluation, with break clause timings yet to be decided.
It is expected that the evaluation supplier will have the capacity to work over a 5 year period, conducting evaluations in different countries across the world simultaneously, if necessary. It will be a requirement of the evaluation supplier to work closely with the management agent of the Fleming Fund during the inception phase to decide how to co-operate in the collection and sharing of compliance data and monitoring of the projects, while remaining independent, shown in an agreed governance structure. This data will allow the evaluator to make formative recommendations at timely points throughout the life of the programme and inform the answering of set summative evaluation questions. We would look for the evaluation supplier to propose a methodology on how they will conduct the evaluation, any additional products they feel would be appropriate to produce and a demonstrated to work through contextual political issues.
The evaluation supplier will need to:
| • | Provide a baseline for each project awarded funding |
| • | Create monitoring questions to feed into each evaluation question, which will be detailed in the terms of reference document |
| • | Provide a mid-programme review, providing formative recommendations if required |
| • | Provide a final report on the summative outcomes and impacts of the Fleming Fund as shown in the theory of change, answering the evaluation questions |
| • | Draw on relevant technical experience of AMR |
| • | Conduct evaluation activities in multiple country and regional projects around the world |
Additional information: A pre-procurement event will be held on the afternoon of the 2nd of March 2016 at Richmond House, 79 Whitehall, London. If you would be interested in attending this event, please email Flemingfund@dh.gsi.gov.uk to register your interest. When expressing an interest organisations should provide:
- (I)the contact details of the service providers representative
- (ii)a single paragraph summary of your organisations experience including whether you are a Small to Medium
sized Enterprise or Voluntary Sector Organisation . This summary may be shared with other participants in order to promote discussion. with a short description of your organisation and a list of attendees with their role description. An agenda and information pack will be sent to you, include a draft terms of reference for comment.
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 18 Nov 2016 | Planning (planning) | · | fda8df74-14ca-4aac-8bda-b4c6c9e6be24-87243 |
more from Department Health
- Meningococcal C or ACWY Vaccine · 23 Aug 2017
- C1-esterase, Icatibant and Conestat Alpha · £15,000,000 · 18 Nov 2016
- Corporate Services Solutions · 18 Nov 2016
- Specialised - Human Cell rFVIII · £5,000,000 · 18 Nov 2016
- External Quality Assessment for DH Internal Audit · £20,000 · 18 Nov 2016
- Specialised Recombinant Factor IX 2016 · £43,221,240 · 18 Nov 2016
- Specialised - Factor X and Porchine Factor VIII · 18 Nov 2016
- Hereditary Angioedema · £15,000,000 · 18 Nov 2016
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Criminal Justice Data Spine Delivery · Home Office · £2,500,000
- Asset Systems Review · THE GUINNESS PARTNERSHIP LIMITED · £60,000
- 260065 Strategic Consultancy Support · Queen's University Belfast · £448,500
- ITT - Archive Strategic Review (UID 267) · Historic England · £25,000
- TEN-2526-048 (PCR15) - Modern Agile, Product Led Delivery (MAPD) Pilot · National Employment Savings Trust (NEST) · £450,000
- Adults Services Improvement Programme · Bedford Borough Council · £5,357,000
- Travel to School Framework Call off · North Northamptonshire Council
- Rio Gap Analysis · Kent and Medway Mental Health NHS Trust · £19,620
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.